Stay updated with breaking news from Astrazeneca Evusheld. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
People infected with the earliest version of the Omicron variant of the coronavirus, first identified in South Africa in November, may be vulnerable to reinfection with later versions of Omicron even if they have been vaccinated and boosted, new findings suggest.
Early omicron infection unlikely to protect against current variants
NEW YORK (Reuters) - People infected with the earliest version of the Omicron variant of the coronavirus, first identified in South Africa in November, may be vulnerable to reinfection with
AstraZeneca's Evusheld provided clinically and statistically significant protection against progression to severe COVID-19 over placebo.
LONDON (dpa-AFX) - British drug major AstraZeneca PLC (AZN.L, AZN) announced positive results of COVID-19 treatment Evusheld in TACKLE Phase III treatment trial. Evusheld significantly prevented